Long Shortz with Dimerix: Tackling rare kidney disease with DMX-200

Tylah Tully chats with Dimerix (ASX:DXB) managing director Dr.Nina Webster about the company’s lead clinical asset DMX-200, currently in Phase 3 trials for focal segmental glomerulosclerosis (FSGS) – a rare, devastating kidney disease with no approved treatments worldwide.

Dr Webster explains the Action-3 study, why FSGS has been such a difficult condition to target, and how global initiatives like Project PARASOL are reshaping regulatory pathways by validating new clinical endpoints.

She also outlines Dimerix’s strong global positioning, bolstered by orphan drug designations in the US, Europe and UK, as well as four major commercial partnerships worth up to $1.4 billion in potential value.

Watch the video to learn more.

This video was developed in collaboration with Dimerix, a Stockhead client at the time of publishing.

The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions.